ALK4290

· Alkahest, Inc.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for ALK4290, covering 2020-08-28 to 2020-08-28. Get the full timeline:

Most recent: Clinical Trial Update: Evaluate the Therapeutic Effects and Safety of ALK4290 in Patients With Refractory Wet Age-Related Macular Degeneration [Phase 2]

See pricing